Trial Profile
Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkins Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antithymocyte globulin; Ciclosporin; Ciclosporin; Mycophenolate mofetil; Mycophenolate mofetil; Rituximab
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Biomarker; Therapeutic Use
- 28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 28 Nov 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Apr 2023.
- 15 Nov 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.